Cingulate Inc. (CINGW) NASDAQ
0.04
+0.0005(+1.43%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Cingulate Inc.
Address
1901 West 47th Place
Kansas City, KS 66205
United States of America (the)
Phone
913 942 2300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
December 08, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Shane J. Schaffer | Co-Founder, CEO & Director | 794,374 | 1975 |
| Matthew N. Brams | Co-Founder, Executive Vice President & Chief Medical Officer | 206,313 | 1964 |
| Nilay Patel | Executive VP, Chief Legal Officer & Chief Compliance Officer | 510,966 | 1978 |
| Jennifer L. Callahan | Executive VP, CFO & Secretary | 619,505 | 1971 |
| Downey Bryan Wade | Executive VP & Chief Commercial Officer | 0 | 1972 |
| Thomas Dalton | Vice President of Investor & Public Relations | 0 | N/A |
| Raul R. Silva | Co-Founder, Executive Vice President & Chief Science Officer | 0 | 1958 |
Description
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
